Abstract: Compounds of formula ##STR1## (wherein R, R.sub.1, R.sub.2 and X have the meanings reported in the specification), the processes for their preparation and the pharmaceutical compositions containing them as active ingredient are described.The compounds of formula I are useful in the treatment of Parkinson's disease, renal failure, cardiac decompensation and hypertension.

Abstract: The compound N,N'-dimethyl-N-(3,4,5-trimethoxybenzyl)-N'-[3,3-di-(4-fluorophenyl)-propy l]-ethylenediamine and its salts are described.This compound is useful in the treatment of several cardiovascular pathologies.

Abstract: Compounds having the formula ##STR1## wherein R is 2-[1-oxo-(2H)-phthalazinyl], R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, X, Y, m and n have the meanings shown in the description. The compounds of formula I are pharmaceutically active as anti-vasospastic, anti-aggregating, and anti-proliferative agents.

Abstract: The compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 have the meanings given in the specification, are described.The compounds of formula I are active as inhibitors of the enzyme HMG-CoA reductase and can be used in therapy as anti-hypercholesterolemics.

Abstract: Basic esters of 1,4-dihydropyridine-3,5-dicarboxylic acid of formula (I) ##STR1## are described, in which R.sup.1 is a linear or branched alkyl radical containing 1-5 carbon atoms which is unsubstituted or substituted by an alkoxy group; R.sup.2 is phenyl or a nitro phenyl radical; R.sup.3 is phenyl, phenyl substituted by one to three radicals selected from (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy, fluoro, chloro, bromo, nitro, cyano, COOR in which R is alkyl of 1 to 4, trifluo carbon atoms, romethyl, hydroxy, amino, mono- or di-alkylamino, mono- or di-acylamino, mercapto, S(O).sub.n -alkyl with n=0, 1 or 2, (C.sub.1-5)acyl, carbamoyl, ureido or R.sup.

Abstract: Pharmaceutical compositions and their use in ophthalmology. Said compositions comprise ibopamine (epinine 3, 4-0-diisobutyrate and are used mainly as mydriatics.

Abstract: A catecholamine compound is converted to a new mono O-phosphate ester derivative thereof which exhibit improved absorption and effectiveness.

Abstract: Pyridinecarboxylic esters of dopamine and of its N-alkyl derivatives, salts thereof with pharmaceutically acceptable organic or inorganic acids, process for preparing them and pharmaceutical compositions containing them which are particularly useful in the treatment of cardiovascular and renal disorders.

Abstract: Pharmaceutical compositions which contain epinine or a pharmaceutically acceptable salt thereof, and allow to reach a release of epinine comprised between 0.5 and 5 .mu.g/Kg/minute.Said compositions are useful in treating congestive heart failures; they stimulate the heart contractility, show a vasodilating and bronchodilating activity as well as a vasodilating activity on specific districts and particularly on the renal district without causing vasoconstrictive and pressor effects.

Abstract: Compounds having general formula I ##STR1## wherein R.sub.1 is hydrogen, lower alkyl, lower alkoxy, alkyl enoxy, halogen, cyano, carboxyamido or ureido group optionally separated from the phenyl ring by a methylene or ethylene bridge;R.sub.2 is hydrogen, halogen, lower alkyl or alkoxy;R.sub.3 is hydrogen, halogen, lower alkyl, lower alkoxy or R.sub.2 and R.sub.3, taken together, are a methylendioxy group;R.sub.4 is hydrogen or lower alkyl,endowed with remarkable cardioselective .beta.-adrenolytic properties, are described.The process for their preparation and pharmaceutical compositions containing them are also described.

Abstract: Derivatives of aminopyridinecarboxylic acids which inhibit the dipeptidyl carboxy peptidase (DPCP), methods for their preparation and pharmaceutical compositions containing them.The compounds have formula: ##STR1## where Z is hydrogen, alkyl having from 1 to 3 carbon atoms, halogen or alkoxy having from 1 to 3 carbon atoms;R1 is hydrogen, alkyl having from 1 to 6 carbon atoms, arylalkyl having from 7 to 12 carbon atoms, aryl having from 6 to 15 carbon atoms;m and n are an integer of from 0 to 4 each provided, however, the m+n is lower than 5;R2 is hydrogen, alkyl having from 1 to 6 carbon atoms or arylalkyl having from 7 to 12 carbon atoms;R3 is hydrogen or acyl having from 1 to 8 carbon atoms;R4 is hydrogen or alkyl having from 1 to 3 carbon atoms;and their pharmaceutically acceptable salts with organic or inorganic acids.

Abstract: Compounds of formula I: ##STR1## are described in which R.sup.1 is a linear or branched alkyl radical containing between 1 and 5 carbon atoms, the alkyl radical being unsubstituted or substituted by an alkoxy group; R.sup.2 is an unsubstituted phenyl of phenyl substituted by a nitro group; R.sup.3 is hydrogen or a linear or branched alkyl residue containing between 1 and 4 carbon atoms, the alkyl radical being unsubstituted or substituted by at least one alkoxy or fluorine atom or both alkoxy and fluorine atoms; R.sup.4 is hydrogen or a linear or branched alkyl containing between 1 and 4 carbon atoms, the alkyl radical being unsubstituted or substituted by alkoxy, carbalkoxy, dialkylamino, 1-aryl or 1-heteroarylpiperazinyl, aryl or a monocyclic 5 or 6 membered heterocycle in which at least one of the heteroatoms is N,O,S such as 1-piperidinyl, 4-morpholinyl or R.sub.4 is alkenyl or cyclo(C.sub.3 -C.sub.

Abstract: New derivatives of 1,2-ethylenediamine and salts thereof endowed with vascular antispasmodic and antiallergic activity; processes for preparing them, some new intermediates useful in their preparation and pharmaceutical compositions containing them.

Abstract: New derivatives of 1,2-ethylenediamine and salts thereof endowed with vascular antispasmodic and antiallergic activity; processes for preparing them, some new intermediates useful in their preparation and pharmaceutical compositions containing them.

Abstract: The magnesium salt of creatinol-O-phosphate, having the formula: ##STR1## is useful in the treatment and in the prevention of the myocardiac infarction.The preparation of the above magnesium salt takes place by reacting creatinol-O-phosphate, as a water solution, with a reactive magnesium compound.The magnesium salt according to the invention may be obtained in either anhydrous or hydrated form and is useful for the preparation of the normal pharmaceutical formulations for the administration by oral and parenteral route.

Abstract: The present invention relates to a method of inducing a response dopamine-like in an animal having impaired cardiovascular and renal functions, comprising administering to said animal an effective amount of a compound having the general formula: ##STR1## wherein R is a secondary or tertiary alkyl radical having from 3 to 7 carbon atoms, and their salts with nontoxic organic and inorganic acids.In particular, the present invention relates to a method of treating cardiac and renal failures comprising administering to a patient suffering therefrom an effective amount of a compound having the above-identified general formula, in suitable pharmaceutical preparations.

Abstract: The N-m-trifluoromethylphenylanthranilates of O-alcoxycarbonylphenyl, having the formula ##STR1## wherein R is an alkyl group, preferably comprising 1 to 4 carbon atoms, besides being of low toxicity, are endowed with anti-inflammatory properties and are adapted for the treatment of inflammatory and thrombotic diseases. The method for the preparation of the above compounds comprises reacting the N-m-trifluoromethylphenylisatoic anhydride with an alkyl salicylate.

Abstract: Novel cardiocirculatory analeptics are prepared, which are epinine esters as obtained by reacting epinine (N-methyldopamine) with branched-chain aliphatic carboxylic acids. Exemplary members are 3,4-di-O-butyrylepinine and 3,4-di-O-pivaloylepinine. These medicaments are effective also by the oral route of administration, contrary to the hitherto commonly used dopamine derivatives which are rapidly destroyed by metabolization when administered orally.

Abstract: A process is disclosed for the interconversion of alkaloids of the heteroyohimbane group, more particularly of tetrahydroalstonine into raubasine, having the formulae ##STR1## according to which the asymmetry center at C-20 is inverted by several steps involving changes of the ring E structure.

Abstract: The invention relates to novel steroid compounds having the formula ##STR1## and their glycoside derivatives containing a pyridazine ring, in which particularly the substituent R.sub.4 is a hydroxy group or a hexopyranoside unit or a chain of two or three hexopyranoside units, as it is normally found in the molecule of the natural glycosides; one or even all the hydroxy groups contained in the R.sub.4 can be either free or etherified or esterified with either a simple carboxylic acid or a carboxylic acid bearing basic groups, or even acetalized with an aldehyde or a ketone, depending on the position and the orientation of a pair of hydroxy groups. The subject compounds are endowed with cardiotonic activity. The invention moreover relates to the process for the preparation of the above compounds and to their therapeutic use.